Cas­sa­va be­ing in­ves­ti­gat­ed by un­named 'gov­ern­ment agen­cies'; Rock­et Phar­ma gives up­dat­ed da­ta on Danon dis­ease

Cas­sa­va Sci­ences likes to fight fire with fire, with CEO Re­mi Bar­bi­er call­ing a cit­i­zen pe­ti­tion to halt de­vel­op­ment on its lead drug a “short at­tack” in Sep­tem­ber. But the noise sur­round­ing the saga has ap­par­ent­ly drawn the at­ten­tion of the US gov­ern­ment.

The biotech re­port­ed in an SEC fil­ing Mon­day that “cer­tain gov­ern­ment agen­cies” have asked Cas­sa­va to pro­vide them with “cor­po­rate in­for­ma­tion and doc­u­ments.” It’s not clear which agen­cies are in­volved in prob­ing Cas­sa­va, or if mul­ti­ple agen­cies are do­ing so, but the com­pa­ny says it’s co­op­er­at­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER